Bolus-Infusion Delays of Alteplase during Thrombolysis in Acute Ischaemic Stroke and Functional Outcome at 3 Months
Table 1
Demographic and clinical characteristics of patients. Data presented as mean [SD] for continuous variables and proportions (%) for categorical variables unless otherwise stated.
Characteristics
Bolus-infusion delays
0–8 minutes ()
>8 minutes ()
Male sex
50
56
Mean age (years)
73 11
7212
Mean weight (kg)
72 14
7616
Mean systolic blood pressure (mmHg)
144 22
14222
Mean diastolic blood pressure (mmHg)
78 15
7615
Mean admission blood glucose (mmol/L)
72
73
Hypertension
71
59
Diabetes mellitus
13
12
Atrial fibrillation
37
45
Congestive cardiac failure
8
4
Hyperlipidaemia
45
45
TIA/amaurosis fugax
10
6
Previous stroke
14
12
Peripheral vascular disease
6
5
Myocardial infarction or ischaemic heart disease
19
30
Current smoker
15
18
Ex-smoker
26
22
Antiplatelet use
53
60
Pre-stroke mRS, median (IQR)
1 (0–2)
1 (0–2)
Mean onset to treatment time (OTT) in minutes; proportions within groups
0–90
7911; 11%
7416; 18%
91–180
13225; 63%
132 26; 64%
181–270
21219; 26%
20922; 18%
0–270
14747
13647
Oxfordshire Community Stroke Project
Total anterior circulatory stroke
41
56
Partial anterior circulatory stroke
45
35
Lacunar stroke
12
6
Posterior circulatory stroke
2
4
Pre-thrombolysis neurological severity per NIHSS score
Median (IQR)*
107–17
14.59–21
Proportions within NIHSS categories (%)**
0–9
49
30
10–19
35
37
>19
16
33
NIHSS—National Institutes of Health Stroke Scale; TIA—Transient Ischaemic Attack; mRS—modified Rankin Score. No significant differences between infusion delays of 0–8 and >8 minutes except for *(Mann Whitney U test, ) and **(Pearson’s χ2 test = 13.1, ).